Despite this, recent pioneering dosimetry data of [177Lu]Lu-PSMA-617 treatment in other tumors with angiogenesis-associated PSMA expression (e.g., glioblastoma multiforme) has proven the possibility of such targeted treatment, without quick washout of radiolabeled compounds [23]. Here, FOLH1 is linked to glioblastoma.